AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 261 min read$LLY

Eli Lilly Gets $1,450 Target as Bernstein Sees Mounjaro Upside

Bernstein raised its price target on Eli Lilly (LLY) to $1,450, citing expected Q3 revenue growth driven by Mounjaro sales. The firm forecasts Q3 revenue of $22.62B and EPS of $5.48, with 2027 estimates revised to $111.4B revenue and $53.09 EPS. LLY shares rose 0.41% intraday.

Original reporting
finance.yahoo.com
Published Oct 26, 2026, 6:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 6:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly Gets $1,450 Target as Bernstein Sees Mounjaro Upside — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The upgrade signals confidence in Lilly's pipeline and upcoming sales, which could attract momentum traders.

02

Market read

Analyst price target upgrades are a common short‑term catalyst; this one may prompt buying in LLY and related biotech stocks.

03

What to watch

Potential competitive pressure from biosimilars and pricing scrutiny.

Relevance 7/10Novelty 7/10Timing: intraday today

Background

Bernstein SocGen Group adjusted its valuation model for Eli Lilly, raising the 2027 revenue outlook and adjusting pricing assumptions.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Bernstein raised its price target for Eli Lilly to $1,450 and kept an Outperform rating, citing modest Q3 revenue upside from international Mounjaro sales.

Expected impact

likely modest upside as investors price in the higher target

Evidence & confidence

The new target reflects fresh earnings expectations and is the first report of this upgrade, providing a concrete catalyst for short‑term buying.

Market effects

Sector

Higher target may lift peer diabetes/obesity drug makers.

Regional

U.S. pharma sector could see modest gains.

Global

Limited to investors tracking Eli Lilly and related biotech stocks.

Counterpoint

What could challenge this read

The target increase may be premature if Mounjaro growth stalls.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company developing Mounjaro and Zepbound.

  • analyst
    Bernstein SocGen Group

    Equity research firm providing the price target upgrade.

Read at source← All news

Related articles

OCT 26
$LLYMed

The Most Powerful Obesity Drug Yet Has a Hidden Benefit—and It Happens While You Sleep

Eli Lilly's obesity drug retatrutide showed significant improvement in obstructive sleep apnea (OSA) symptoms in two trials, reducing episodes and potentially eliminating the need for airway pressure machines. The drug, which mimics GLP-1, GIP, and glucagon, is expected to gain FDA approval next year. Trials included 700 participants with obesity, with and without type 2 diabetes, and results were published in the New England Journal of Medicine.

gizmodo.com6 min
OCT 26
$LLYHigh

Investigational Med Tied to Major Reduction in OSA Severity

Eli Lilly's investigational weight-loss drug retatrutide significantly reduced obstructive sleep apnea (OSA) severity in phase 3 trials. At 80 weeks, patients saw substantial reductions in breathing interruptions and weight loss compared to placebo. The drug also improved sleep-related impairment and reduced hypoxic burden. Eli Lilly funded the studies and participated in their design and analysis.

medscape.com3 min
OCT 26
$LLYMed

Scientists Tested a Toad Venom Psychedelic on Treatment-Resistant Depression. Here's What Happened.

A phase 2b trial funded by AtaiBeckley (Eli Lilly subsidiary) tested a toad venom-derived psychedelic, mebufotenin, as a nasal spray for treatment-resistant depression. The study, published in JAMA, found that an 8 mg dose improved depression scores and was safe, with benefits lasting up to eight weeks. The drug will proceed to phase 3 trials. Critics note the antidepressant effect was modest and the study had limitations.

sciencealert.com3 min
OCT 26
$LLYMed

Eli Lilly Stock Gets a Lift as New Lung Cancer Data Raises Hopes

Eli Lilly's stock rose 1% in pre-market trading after positive clinical data for its experimental drug olomorasib in lung cancer treatment. The drug, paired with immunotherapy and chemotherapy, showed tumor shrinkage in 62% of patients. Median progression-free survival was 11.6 months. Separate study with Merck's Keytruda showed 55% of patients alive without disease progression at 18 months. Phase 3 trial results are expected in 2027.

gurufocus.com1 min
OCT 26
$AZNMedAI 8/10

Breakfast News: Science Strikes Back at Cancer

AstraZeneca's stomach cancer drug doubled survival, Eli Lilly's lung cancer treatment showed 62% tumor shrinkage, Moderna/Merck's vaccine reduced recurrence risk by 42%, Amgen's therapy extended survival, and Roche's drug outperformed rivals. U.S. stocks fell due to AI jitters and oil price spikes, with Fed rate decisions looming. Earnings reports from Visa, Alphabet, and others are upcoming. TransDigm's stock declined despite strong sales due to higher interest rates and oil price concerns.

fool.com3 min
OCT 26
$LLYMed

Lilly Reports Olomorasib Results, Eyes First Phase 3 Data In H1 2027

Eli Lilly (LLY) presented updated Phase 1/2 and Phase 3 trial data for olomorasib, a KRAS G12C inhibitor, in combination with immunotherapy for NSCLC. The trials showed promising results, with durable activity and manageable safety profiles. Lilly expects first Phase 3 data in H1 2027. LLY stock closed at $1,273 on Friday, up 0.64% in pre-market trading.

rttnews.com2 min